explore -WSS

explore

author：fashion 2025-09-27 17:02:44 - browse：63

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CDC director unscathed in first congressional testimony

WSS

How to pay for weight loss drugs and save Medicare

MultiPlan and major insurers sued for alleged medical price

Fetal surgery at risk from Dobbs and new abortion restrictions

MassMutual is introducing free genetic testing for members

Key Senate committee drafts bipartisan bill to stem drug shortages

30 years of 'Listening to Prozac'

explore

explore

Bluebird and the case for gene therapy profits

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

MultiPlan and major insurers sued for alleged medical price

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Dogs on Prozac: What pet anti

The cancer drug shortage isn’t new — and neither are the solutions

Rep. Raul Ruiz on the physician shortage and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Dogs on Prozac: What pet anti

How to save PrEP access — and even expand it

Cue Health's Covid

leisure time

Exact Sciences stock tumbles despite strong cancer detection sales

Element Biosciences CEO lays out genome sequencing strategy

Orangutan used medicinal plant to treat wound, first time ever seen

H5N1 bird flu virus started spreading in cows in Texas in December

Will the market for weight loss drugs really reach $100 billion?

ReNAgade cuts staff seven months after raising $300 million

leisure time

explore

Wikipedia

hotspot